Triple Agonist

Retatrutide

Next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon pathways

Overview

Retatrutide is an investigational triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple-action mechanism produces some of the most significant weight loss results seen in clinical trials to date. By targeting three metabolic pathways at once, retatrutide enhances fat burning, reduces appetite, and improves metabolic function beyond what single or dual agonists achieve.

Obesity and significant weight management
Metabolic syndrome improvement
Blood sugar regulation
Enhanced fat oxidation
Appetite and food craving reduction

Dosage & Instructions

Form

Subcutaneous injection

Amount

As prescribed by your provider

Frequency

Once weekly

Timing

Same day each week

Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate sites. Follow your provider's titration schedule.

Dosage Schedule

When	Dose	Notes
Initial phase	Starting dose as prescribed	Gradual titration to minimize side effects
Titration phase	Increasing per provider plan	Dose adjusted based on tolerance and response
Maintenance	Target dose as directed	Continue weekly injections as prescribed

Side Effects

Common

Nausea
Vomiting
Diarrhea
Decreased appetite
Constipation

Less Common

Fatigue
Injection site reactions
Dizziness
Abdominal discomfort

Serious — Seek Care

Pancreatitis — stop and contact provider if severe abdominal pain occurs
Gallbladder issues
Hypoglycemia in combination with other diabetes medications

Drug Interactions